179 related articles for article (PubMed ID: 21606960)
21. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
22. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Lanasa MC; Andritsos L; Brown JR; Gabrilove J; Caligaris-Cappio F; Ghia P; Larson RA; Kipps TJ; Leblond V; Milligan DW; Janssens A; Johnson AJ; Heerema NA; Bühler A; Stilgenbauer S; Devin J; Hallek M; Byrd JC; Grever MR
Leuk Res; 2015 May; 39(5):495-500. PubMed ID: 25804339
[TBL] [Abstract][Full Text] [Related]
23. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
24. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
Koehler AB; Leung N; Call TG; Rabe KG; Achenbach SJ; Ding W; Kenderian SS; Leis JF; Wang Y; Muchtar E; Hayman SR; Hampel PJ; Finnes HD; Schwager SM; Slager SL; Kay NE; Parikh SA
Leuk Lymphoma; 2020 Oct; 61(10):2383-2388. PubMed ID: 32449401
[TBL] [Abstract][Full Text] [Related]
25. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
27. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
[TBL] [Abstract][Full Text] [Related]
28. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
[TBL] [Abstract][Full Text] [Related]
29. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
30. Flavopiridol in the treatment of chronic lymphocytic leukemia.
Christian BA; Grever MR; Byrd JC; Lin TS
Curr Opin Oncol; 2007 Nov; 19(6):573-8. PubMed ID: 17906454
[TBL] [Abstract][Full Text] [Related]
31. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Shapiro GI; Supko JG; Patterson A; Lynch C; Lucca J; Zacarola PF; Muzikansky A; Wright JJ; Lynch TJ; Rollins BJ
Clin Cancer Res; 2001 Jun; 7(6):1590-9. PubMed ID: 11410495
[TBL] [Abstract][Full Text] [Related]
33. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Mahoney E; Byrd JC; Johnson AJ
Autophagy; 2013 Mar; 9(3):434-5. PubMed ID: 23422081
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P; Perkins EB; Honeycut C; Wellons MD; Stefan T; Jacobberger JW; Kontopodis E; Beumer JH; Egorin MJ; Imamura CK; Douglas Figg W; Karp JE; Koc ON; Cooper BW; Luger SM; Colevas AD; Roberts JD; Grant S
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1657-67. PubMed ID: 22349810
[TBL] [Abstract][Full Text] [Related]
35. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
36. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
Montesinos P; Lorenzo I; Martín G; Sanz J; Pérez-Sirvent ML; Martínez D; Ortí G; Algarra L; Martínez J; Moscardó F; de la Rubia J; Jarque I; Sanz G; Sanz MA
Haematologica; 2008 Jan; 93(1):67-74. PubMed ID: 18166787
[TBL] [Abstract][Full Text] [Related]
37. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Lin TS
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
[TBL] [Abstract][Full Text] [Related]
38. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
[TBL] [Abstract][Full Text] [Related]
39. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
[TBL] [Abstract][Full Text] [Related]
40. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
Gribben JG
Br J Haematol; 2020 Mar; 188(6):844-851. PubMed ID: 31858596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
